Is diclofenac a valuable CYP2C9 probe in humans?

European Journal of Clinical Pharmacology

Volumn 56, Issue 11, 2001, Pages 793-797

  Morin, S ^a   Loriot, M A ^b   Poirier, J M ^a   Tenneze, L ^a   Beaune, P H ^b   Funck Brentano, C ^a   Jaillon, P ^a   Becquemont, L ^a,c  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSERM   (France)

^c Saint Antoine Paris University Hospital Center   (France)

Author keywords

CYP2C9; Diclofenac; Genotype

Indexed keywords

CYP2C9 PROTEIN, HUMAN; CYTOCHROME P450; DICLOFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID 16ALPHA MONOOXYGENASE; STEROID MONOOXYGENASE; UNSPECIFIC MONOOXYGENASE;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; ENTERIC COATED TABLET; FEMALE; GENETICS; GENOTYPE; HUMAN; MALE; METABOLISM; MIDDLE AGED;

ADULT; ALLELES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DICLOFENAC; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TABLETS, ENTERIC-COATED;

EID: 0034465025     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000240     Document Type: Article

References (21)

1. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR (1994) Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4: 39-42
2. Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT (1999) Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 9: 71-80
3. Brian WR, Srivastava PK, Umbenhauer DR, Lloyd RS, Guengerich FP (1989) Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 28: 4993-4999
4. McCrea JB, Cribb A, Rushmore T, et al (1999) Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174 (clinical conference). Clin Pharmacol Ther 65: 348-352
5. Furuya H, Fernandez-Salguero P, Gregory W, et al (1995) Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5: 389-392
6. Yasar U, Eliasson E, Dahl ML, Johansson I, IngelmanSundberg M, Sjoqvist F (1999) Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 254: 628-631
7. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE (1996) Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity. and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 333: 447-458
8. Aithal GP, Day CP, Kesteven PJ, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353: 717-719
9. Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJ (1990) Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 47: 403-411
10. Veronese ME, Miners JO, Rees DL, Birkett DJ (1993) Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects. Pharmacogenetics 3: 86-93
11. Aynacioglu AS, Brockmöller J, Bauer S, et al (1999) Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 48: 409-4115
12. Tassaneeyakul W, Birkett DJ, Pass MC, Miners JO (1996) Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo. Br J Clin Pharmacol 42: 774-778
13. Bort R, Mace K, Boobis A, Gomez-Lechon MJ, Pfeifer A, Castell J (1995) Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol 58: 787-796
14. Transon C, Leemann T, Vogt N, Dayer P (1995) In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. Clin Pharmacol Ther 58: 412-417
15. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR (1996) Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6: 429-439
16. Prober JM, Trainor GL, Dam RJ, et al (1987) A system for rapid DNA sequencing with fluorescent chain-terminating dideoxynucleotides. Science 238: 336-341
17. Chan KK, Mojaverian P, Ziehmer BA, John VA (1990) Application of radiotelemetric technique in evaluating diclofenac sodium absorption after oral administration of various dosage forms in healthy volunteers. Pharm Res 7: 1026-1032
18. Willis JV, Jack DB, Kendall MJ, John VA (1981) The influence of food on the absorption of diclofenac as determined by the urinary excretion of the unchanged drug and its major metabolites during chronic administration. Eur J Clin Pharmacol 19: 39-44
19. Bogentoft C, Carlsson I, Ekenved G, Magnusson A (1978) Influence of food on the absorption of acetylsalicylic acid from enteric-coated dosage forms. Eur J Clin Pharmacol 14: 351-355
20. Willis JV, Kendall MJ, Flinn RM, Thornhill DP, Welling PG (1979) The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol 16: 405-410
21. Willis JV, Kendall MJ, Jack DB (1981) The influence of food on the absorption of diclofenac after single and multiple oral doses. Eur J Clin Pharmacol 19: 33-37